VALOR Skin Outcomes with Brepocitinib in Dermatomyositis Save

Article

Brepocitinib Skin Outcomes in Patients With Dermatomyositis

Jack Cush, MD · Aug 26, 2026

A secondary analysis of the VALOR trial has shown that the TYK2/JAK1 inhibitor brepocitinib was effective at cutaneous disease activity outcomes, delivering rapid, clinically meaningful, and remission-level control of cutaneous dermatomyositis (DM).This was a prespecified secondary analysis of the…

Article

FDA Approves Brepocitinib to Treat Dermatomyositis

Jack Cush, MD · Aug 31, 2026

The FDA and Priovant recently annouced approval of brepocitinib (Lisraya), a JAK1/TYK2 inhibitor, for the indication of adults with dermatomyositis (DM). This is the first oral (once daily) agent approved for DM.

Article

EBR Journal Club: Brepocitinib in Dermatomyositis (VALOR)

Michael Putman, MD, MSCI · Oct 6, 2026

The EBR Journal Club Companion applies my adapted version of the JAMA approach to critical appraisal. Each review covers four domains: Does this apply to my patients? What is the risk of bias? How great are the benefits and harms? And what didn’t they show me? Feel free to use this in your own journal clubs! This edition: VALOR (brepocitinib in dermatomyositis).